Close menu




FRESENIUS SE+CO.KGAA O.N.

Photo credits: pixabay.com

Commented by Juliane Zielonka on April 22nd, 2024 | 07:00 CEST

Cardiol Therapeutics, Bayer AG, Fresenius - Who will be the trendsetter in tomorrow's healthcare market?

  • Biotechnology
  • Pharma
  • Healthcare

The healthcare sector is a lucrative segment for risk-conscious investors. The global healthcare services market size is expected to achieve a compound annual growth rate (CAGR) of 8.96% linkedin.com/pulse/healthcare-services-market-size-share-2023-cmxbc by 2028. Understanding local healthcare needs is the basis for the growth of companies such as Cardiol Therapeutics, Bayer and Fresenius. Cardiol Therapeutics is a promising life sciences company researching several heart diseases with a focus on heart health and developing suitable medication. A disease such as heart failure (HF), for example, affects 26 million people worldwide and offers high scaling potential for the Canadian researchers and developers at Cardiol. Bayer also recognizes the market potential and would like to supply this target group with a gene therapy via Fast Track. Fresenius is familiar with market conditions due to expiring patent protection and is launching a lucrative biosimilar in the US. Which of these three companies will set the trend in the healthcare market of the future?

Read

Commented by Juliane Zielonka on February 22nd, 2024 | 07:00 CET

Royal Helium, Fresenius, BASF: Chemical and Healthcare industry - Where is the next investment opportunity?

  • Helium
  • Healthcare
  • chemicals

Europe is in the midst of an industrial upheaval due to the Green Deal, which presents both challenges and opportunities for investors. While companies like BASF are arguing for deregulation and increased subsidies to support the green transition, healthcare company Fresenius is undergoing a period of radical change and realignment. The medical technology market is booming. The global MedTech market size amounted to USD 574,002.45 million in 2022 and is expected to increase to USD 814,159.2 million by 2028, with an annual growth rate of 6.0%. Critical raw materials such as helium are in particularly high demand. Royal Helium is one of the producers of this valuable gas and impresses with a well thought-out and sustainable business model. Where does the next investment opportunity lie?

Read

Commented by Juliane Zielonka on May 11th, 2023 | 07:55 CEST

Manuka Resources, Fresenius, Amazon - Gold to offset economic dismantling and restriction measures?

  • Mining
  • Gold
  • Healthcare
  • Technology

For decades, the annual production of gold has been increasing. In 2020, a total of 3200 tonnes of gold was produced, with China as the largest gold producer in the world, followed by Australia and Russia. Manuka Resources is an explorer and gold producer in Australia. The Company has now developed a 3-year gold production plan to give its shareholders the most value possible. A solid precious metal like gold can provide balance in turbulent times. Fresenius, for example, is in the midst of a turnaround and is reporting its first results. Things can get tight for Amazon, Microsoft and Alphabet if the EU enforces its new cybersecurity directives - but this can also turn out to be an advantage.

Read

Commented by Nico Popp on August 2nd, 2022 | 10:57 CEST

These sources of return concern us all: Fresenius, Defence Therapeutics, BioNTech

  • Biotechnology

When people receive an unexpected diagnosis or a loved one suddenly dies, our health suddenly becomes very important. Even though there is often no room for such topics in the daily lives of investors, it is worthwhile to deal with health for several reasons. On the one hand, preventive care brings the most important of all returns; on the other hand, this rather unpleasant topic in everyday life also holds opportunities if we focus on health risks and look at possible solutions. We present three stocks from the healthcare sector that deserve attention.

Read

Commented by André Will-Laudien on September 16th, 2021 | 11:58 CEST

Siemens Healthineers, PuriflOH, Fresenius, Novavax - Focusing on health!

  • Investments

The pandemic outbreak in 2020 ushered in a new era. People's health is once again moving to the center of attention. Politicians worldwide see themselves obligated to make public life safe, but whether this will be 100% successful remains questionable. Ultimately, it will depend on the commitment of private companies to what extent the existing health issues can be solved and by what means. On the capital markets, the healthcare sector has been sailing on the highest wave for months because the dangers for billions of people need to be reduced, and framework conditions for public life need to be created. Who benefits the most?

Read

Commented by Carsten Mainitz on March 17th, 2021 | 07:30 CET

Royal Dutch Shell, Pollux Properties, Fresenius SE - Value stocks with some catching up to do!

  • RealEstate

Last year's Corona shock initially sent almost all shares into a tailspin. While some were able to recover relatively quickly and in some cases started massive price rallies, so-called value stocks had a hard time. Now, the rotation towards value stocks has partially begun. In the following, we will show you 3 stocks where you can still make a bargain. Seize the opportunity!

Read

Commented by Nico Popp on March 17th, 2021 | 07:25 CET

Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends

  • Healthcare

The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.

Read

Commented by Nico Popp on February 8th, 2021 | 07:30 CET

Fresenius, Fresenius Medical Care, Q&M Dental: Healthy returns await here

  • Health

Healthcare stocks have been in demand not just since the pandemic, but the pandemic is a sure game-changer for the industry in the long term. Demand for consumables and tests will continue to rise because this much seems certain: the Coronavirus will remain with us and possibly return year after year like a wave of influenza. Companies in the industry can profit from this. We present three stocks.

Read

Commented by André Will-Laudien on January 28th, 2021 | 10:39 CET

Fresenius - Q&M Dental Group - IBU-tec: New price explosions every day!

  • Health

Rarely has the stock market been so volatile and exciting as in the last few days. Hedge fund Melvin Capital had to close out because of the GameStop share, and now the next wave is probably looming with AMC Entertainment. A full 270% went through the roof right at the opening; according to the New York Stock Exchange (NYSE) thousands of buy orders were already there at opening. Again, there had been a recommendation in a social media channel. On the Nasdaq, it jumped rapidly from USD 5 to USD 21 right at the opening - something you rarely see. And GameStop continues today after yesterday's debacle! After several trading suspensions, the value exploded further from USD 149 to USD 380 after a good hour of trading. That should have been the end of trading school for many new entrants!

Read

Commented by Mario Hose on January 15th, 2020 | 07:42 CET

Fresenius Peer: Will the analysts' favorite M1 Kliniken 2020 take off?

  • Medical

Besides Fresenius, M1 Klinken AG is one of the few listed clinic operators in Germany. Unlike the clinic group, M1 has specialised in a lucrative niche: the beauty market. More and more people are helping with beauty and are generating billions in sales in the industry. In just a few years, M1 has become the market leader for beauty medicine in Germany. A growth rate of 30% is also targeted for the future. Foreign business is increasingly becoming the growth driver. After a continuous price increase between 2016 and 2018, the share has consolidated in 2019. But operationally things are still running smoothly. Analysts see more than 50% upside potential.

Read